Crossref
FDA approves drug to treat neurologic manifestations of Hunter syndrome
The Brown University Child & Adolescent Psychopharmacology Update · 2026-05 · 28 (5) · 8-8
DOI: 10.1002/cpu.31062 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Child & Adolescent Psychopharmacology Update, online erschienen am 27.04.2026.
Abstract (Originalsprache)
The U.S. Food and Drug Administration approved Avlayah to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).
Zitieren
APA
(2026). FDA approves drug to treat neurologic manifestations of Hunter syndrome. The Brown University Child & Adolescent Psychopharmacology Update, 28(5), 8-8. https://doi.org/10.1002/cpu.31062
Vancouver
FDA approves drug to treat neurologic manifestations of Hunter syndrome. The Brown University Child & Adolescent Psychopharmacology Update. 2026;28(5):8-8. doi:10.1002/cpu.31062
BibTeX
@article{euvimed2026,
title = {FDA approves drug to treat neurologic manifestations of Hunter syndrome},
journal = {The Brown University Child & Adolescent Psychopharmacology Update},
year = {2026},
volume = {28},
number = {5},
pages = {8--8},
doi = {10.1002/cpu.31062}
}
EUVIMED